High Dose Mitomycin C with Bone Marrow Transplant in Liver Cancer
Author Information
Author(s): R.E.T. Corringham, R. Dick, M.J.M.L. Gilmore, H.G. Prentice, E.M. Boesen
Primary Institution: Royal Free Hospital and School of Medicine
Hypothesis
Can high dose Mitomycin C followed by autologous bone marrow transplantation be safely administered to patients with metastatic liver cancer?
Conclusion
The study suggests that high dose Mitomycin C can be safely administered via hepatic arterial infusion followed by autologous bone marrow transplantation, showing a high response rate in a small group of patients.
Supporting Evidence
- One patient with breast cancer achieved complete remission lasting 34 weeks.
- Two patients had partial responses lasting 6 weeks.
- Haematological recovery was rapid in 3 out of 4 patients.
Takeaway
Doctors tested a strong medicine called Mitomycin C to help people with liver cancer, and it seemed to work well for some of them.
Methodology
The study involved administering high dose Mitomycin C either intravenously or via hepatic arterial infusion, followed by autologous bone marrow transplantation in patients with metastatic liver cancer.
Limitations
The study had a very small sample size and did not investigate the pharmacokinetics of the drug delivery method.
Participant Demographics
Patients included two with breast adenocarcinoma, one with rectal adenocarcinoma, and one with cholangiocarcinoma, with a mean age of 33 years.
Want to read the original?
Access the complete publication on the publisher's website